We may earn a commission when readers sign up through partner links. Rankings reflect our published methodology, not advertiser fees.
GLP·Agonists Editor's Pick

Condition · Evidence Review

GLP-1 and Obstructive Sleep Apnea: SURMOUNT-OSA, Zepbound

Fact-checked by Dr. Adam Kennah, MD on . See our fact-checking policy.

On December 20, 2024, the FDA approved tirzepatide (Zepbound) for moderate-to-severe obstructive sleep apnea in adults with obesity — the first drug ever approved for OSA. The basis was the SURMOUNT-OSA program, where tirzepatide reduced the apnea-hypopnea index by ~30 events per hour at 52 weeks, with about half of participants achieving disease remission.

Key facts

  • FDA approval: Tirzepatide for moderate-to-severe OSA + obesity, December 20, 2024.
  • SURMOUNT-OSA result: AHI reduction of ~30 events/hr vs ~6 events/hr placebo at 52 weeks. ~43–52% of treated participants achieved AHI <5 or AHI <15 with no symptoms (disease remission).
  • Mechanism: Weight loss reduces upper-airway adiposity and ventilatory drive; possibly additional effects on respiratory neural control.
  • Semaglutide: No FDA OSA indication. Effect on AHI inferred but not formally tested at OSA scale.

What SURMOUNT-OSA showed

The SURMOUNT-OSA program enrolled 469 adults with moderate-to-severe OSA (AHI ≥15) and obesity, in two parallel trials: one with concurrent PAP therapy, one without. Participants received tirzepatide 10–15 mg or placebo for 52 weeks.

In the no-PAP arm, mean AHI decreased by 27.4 events/hr with tirzepatide vs 4.8 with placebo. In the PAP arm, the absolute reduction was even larger because baseline AHI under PAP was higher. About half of treated participants met criteria for disease remission.

Why this matters clinically

OSA affects an estimated 25 million U.S. adults and is profoundly undertreated — PAP adherence is poor, surgical options are invasive, and oral appliances have modest efficacy. A pharmacologic option that addresses the underlying pathophysiology (obesity-driven upper-airway loading) is genuinely novel.

This is not a replacement for PAP in patients who tolerate it. Rather, it is an option for patients who cannot or will not use PAP, or as an adjunct to PAP to reduce required pressures and improve adherence.

Does compounded tirzepatide work for OSA?

Compounded tirzepatide delivers the same active molecule. The pharmacologic basis for benefit is therefore the same. However, compounded versions are not FDA-approved for any indication, including OSA. Insurance reimbursement for OSA treatment is therefore tied to brand-name Zepbound only.

Practical workflow

  1. Confirm OSA diagnosis with a sleep study (AHI ≥15 for moderate-to-severe).
  2. Confirm BMI ≥30 (or ≥27 with comorbidities per FDA label).
  3. Initiate tirzepatide with standard 2.5 mg starting dose and titrate per package insert.
  4. Repeat sleep study at 6–12 months to document AHI response.
  5. Continue or adjust PAP therapy in parallel.

What about semaglutide?

Semaglutide has not been studied at scale for OSA. Smaller observational data suggests AHI improvement scales with weight loss, which is what you would expect mechanistically. But there is no semaglutide trial at the SURMOUNT-OSA level, and no FDA OSA indication.

References

SURMOUNT-OSA (Malhotra et al., NEJM 2024). FDA approval announcement, December 20, 2024. See our research bibliography for full citations.